Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589998 | 0.82 | NPC1 (0.57) | ALDH1A1NPC1RAB9AIDO1 | |
| SCHEMBL3537551 | 0.77 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1KMT2APOLBKCNMA1 | |
| SCHEMBL46863 | 0.76 | ALDH1A1 (0.68) | SMN1; SMN2ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL27626419 | 0.75 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL339922 | 0.75 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL26099699 | 0.74 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL26099697 | 0.74 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6591721 | 0.74 | P2RX1 (0.64) | SMN1; SMN2ALDH1A1KMT2AMEN1KCNMA1 | |
| SCHEMBL19554297 | 0.74 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL25391003 | 0.73 | RAB9A (0.57) | SMN1; SMN2NPC1RAB9AIDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2093223-B1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-08-21 | — | — | EP | disclosed |
| CN-103204811-A | Process For Production Of Anthranilamide Compound | ISHIHARA SANGYO KAISHA | 2013-07-17 | — | — | CN | disclosed |
| CN-101558056-B | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA | 2013-05-01 | — | — | CN | disclosed |
| US-8115006-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA ,LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| CN-101558056-A | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA (JP) | 2009-10-14 | — | — | CN | disclosed |
| EP-2093223-A1 | PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | NAAA, AAAS, AADAC | SMN1; SMN2 4856/4885ALDH1A1 993/4885NPC1 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.